Effectiveness of treatment with oral paricalcitol in patients with pre-dialysis chronic kidney disease.

Secondary hyperparathyroidism is a common complication in patients with chronic kidney disease. Treatment with paricalcitol, a selective vitamin D receptor (VDR) activator, has shown benefits in these patients by adequately reducing PTH levels with minimal changes in serum calcium and phosphorus. The aim of this study was to assess the effectiveness and safety of paricalcitol in chronic renal disease patients (CKD grades 3 and 4).
A study of our experience with paricalcitol was conducted in normal clinical practice in patients over 18 years diagnosed with grade 3 or 4 chronic kidney disease. Patients were periodically evaluated every 3 months. The primary endpoint of effectiveness was to obtain two consecutive decreases of ≥30% in iPTH with respect to baseline values. The secondary endpoints were fulfilment of the objectives in accordance with the Spanish Society of Nephrology (SEN) and Kidney Disease Outcomes Quality Initiative (K/DOQI) guidelines, as well as the relationship between the effectiveness of the treatment and different patient variables. Safety was studied by means of hypercalcaemia events.
The primary study endpoint was achieved in 54.3% of patients. In addition, another 16.3% of patients had reduced iPTH by more than 30% at the 3rd visit. Therefore, 70.6% of patients reduced their iPTH levels by more than 30% in 6 months. The relationship between treatment success and both glomerular filtration rate and body mass index was significant. There were few adverse events, although hypercalcaemia was found in 5.4% of patients.
Treatment with paricalcitol is effective in controlling secondary hyperparathyroidism in non-dialysed patients with a wide safety margin.
AuthorsJosé Gregorio Hervás Sánchez, María Dolores Prados Garrido, Aurora Polo Moyano, Sebastian Cerezo Morales
JournalNefrología : publicación oficial de la Sociedad Española Nefrologia (Nefrologia) Vol. 31 Issue 6 Pg. 697-706 ( 2011) ISSN: 1989-2284 [Electronic] Spain
PMID22130286 (Publication Type: Journal Article)
Chemical References
  • Ergocalciferols
  • Parathyroid Hormone
  • Phosphorus
  • paricalcitol
  • Calcium
  • Aged
  • Aged, 80 and over
  • Body Mass Index
  • Calcium (blood)
  • Chronic Disease
  • Diabetic Nephropathies (blood, complications)
  • Dose-Response Relationship, Drug
  • Drug Evaluation
  • Endpoint Determination
  • Ergocalciferols (administration & dosage, therapeutic use)
  • Female
  • Follow-Up Studies
  • Glomerular Filtration Rate
  • Humans
  • Hypercalcemia (etiology, prevention & control)
  • Hyperparathyroidism, Secondary (blood, drug therapy, etiology)
  • Kidney Diseases (complications)
  • Male
  • Middle Aged
  • Parathyroid Hormone (blood)
  • Phosphorus (blood)
  • Retrospective Studies
  • Severity of Illness Index
  • Treatment Outcome

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!

Choose Username:
Verify Password: